A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Key Who May Qualify: - Confirmed genetic diagnosis of primary photoreceptor (PR) disease - Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.0. BCVA at Screening for Phase 2: ETDRS letter score 20 and 60. - Retinal structure examination in the study eye demonstrating regions suitable for cell administration. Key Who Should NOT Join This Trial: - History of/currently active clinically relevant, ocular inflammation or infection - Glaucoma or other significant optic neuropathy - Diabetic macular edema or diabetic retinopathy - Clinically significant cystoid macular edema - Spherical equivalent refractive error of greater than 8.00 diopters myopia - Ocular surgery ≤3 months before Screening - Monocular vision (ie, no light perception in the fellow eye) - Presence of clinically significant anti-OpCT-001 Human Leukocyte Antigen (HLA) antibodies at Screening - Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated. - Any current and active infection (bacterial/viral/fungal) that could put the participant at risk from immunosuppression - History of any cell therapy, gene therapy, or retinal implant at any time - Previously received a bone marrow or solid organ transplant Always talk to your doctor about whether this trial is right for you.